Open AccessEFFICACY OF ARIPIPRAZOLE IN TREATMENT OF SCHIZOPHRENIA IN POPULATION OF CENTRAL INDIA
Author(s) -
Omprakash Raichandani,
Abdul Faheem Khan,
Sapna Raichandani
Publication year - 2020
Publication title -
international journal of medical and biomedical studies
Language(s) - English
Resource type - Journals
eISSN - 2589-8698
pISSN - 2589-868X
DOI - 10.32553/ijmbs.v4i1.968
Subject(s) - aripiprazole , schizoaffective disorder , schizophrenia (object oriented programming) , morning , medicine , population , psychiatry , psychology , psychosis , environmental health
Background: During the past decade, there has been some progress in the pharmacotherapy of schizophrenia and schizoaffective disorder. Aripiprazole is recommended at a dose of between 10 and 15 mg/day in the treatment of schizophrenia, with a dose range considered to be effective, between 10 and 30 mg/day.
Objective: To study the efficacy and safety of Aripiprazole in low doses of 15 mg versus high doses of 30 mg in the treatment of Schizophrenia.
Methods: Total 60 new and old patients (who are not on any treatment) between 18-60 years of either gender who meet the diagnostic criteria as per DSM-IV classification for schizophrenia and schizoaffective disorder. Patients were randomly divided into 2 groups on single blind study criteria. Group-I: Aripiprazole 15 mg once a day, morning dose for 6 weeks. Group-II: Aripiprazole 30 mg once a day, morning dose for 6 weeks. Efficacy assessment included at baseline and at 6 weeks end study scoring on PANSS, EPRS and CGI.
Results: In both the groups aripiprazole showed the efficacy by improving the number of patients. In group-I, 20 patients has shown the improvement in overall scores of all scales. In group-II, 16 patients have shown the improvement in overall scores in different scales.
Conclusions: Aripiprazole is effective in schizophrenia and schizoaffective disorder, low doses of 15 mg is equally effective as high dose of 30 mg.
Keywords: Efficacy, Aripiprazole & Schizophrenia.